The global biosimilars market should reach $60.1 billion by 2025 from $15.7 billion in 2020 at a compound annual growth rate (CAGR) of 30.9% for the forecast period of 2020 to 2025.
3S Bio Inc.
Bio-Thera Solutions Ltd.
Bioxpress Therapeutics S.A.
Blau Farmaceutica S/A
Boehringer Ingelheim Pharmaceuticals Inc.
Chong Kun Dang Pharmaceutical Corp.
Coherus Biosciences Inc.
DM Bio Ltd.
Dong-A Socio Holdings
And Many More Companies!
Biosimilar drugs have gained immense popularity because of their impact on the lives of many patients. These drugs belong to several drug classes including hormones, interferons, growth factors (colony stimulating factors, erythropoietin) and monoclonal antibodies, among others. The use of these drugs has aided in the affordable treatment of many life-threatening diseases ranging from cancer and diabetes to chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and others. The high cost of branded biologics has made biosimilars a lucrative alternative for affordable treatment. According to this report on biosimilars, the global market for biosimilars is expected to reach close to $20.8 billion by 2022, growing at a CAGR of 30.5%. Other drivers for this market include rising aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.
This updated report provides an in-depth analysis of the market for biosimilars in a global context, including market forecasts and sales through 2025. This study surveys the market for biosimilars in all the geographic regions including North America, Europe, the developed rest of the world (RoW), and emerging markets. The emerging markets include countries like India, China, Taiwan, Africa and Latin America.
The report provides an analysis of the market for biosimilars in various segments, for instance, by type, by region and by application/disease category. The report will include a detailed overview about the subject wherein the classification of biosimilar drugs along with their approval mechanisms, clinical trials and applications under review are elaborated upon.
The report also provides relevant patent analysis in both the U.S. and the European Union and comprehensive profiles of companies that lead the biosimilar drugs industry. The industry structure, focusing on the important biosimilar drug manufacturers/suppliers and their market shares and product offerings, is analyzed. This report also discusses the current market situation by elaborating upon the market drivers, restraints, challenges and opportunities. Separate chapters discuss the regulatory aspects and clinical trials. The latest news pieces including new products, new indications, mergers and acquisitions in the market are also dealt with in sufficient detail.
Excluded from this report are biobetters, generics of small molecule drugs and the biogenerics pertaining to vaccines and blood products. The different requirements for approval and bioequivalence between generics and biosimilars put them in an entirely different regime.
The Report Includes
69 data tables and 73 additional tables
An updated review and industry insights of the global biosimilars market
Analyses of the global market trends, with data from 2018 to 2020, and projections of compound annual growth rates (CAGRs) through 2025
Highlights of the emerging market regulations, clinical trials, and new products launches; and their impact on the stakeholders in this market
Discussion of the biosimilars industry structure, opportunities and complexities, regulatory updates and penetration of biosimilar product classes in various regions worldwide
Estimation of current market size and potential growth forecast for biosimilars market, and corresponding market share analysis by product type, application/disease category and geographic region
A detailed review of patents issued for biosimilars by different assignee categories
Impact analysis of COVID-19 pandemic on the growth of biosimilars market as compared to overall pharmaceuticals industry with respect to clinical trials/approvals
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Terminology of Biosimilars
Definitions of Biosimilars
Development of a Biosimilar
Clone Development and Selection
Manufacture of a Biosimilar
Preclinical Studies and Validation of a Biosimilar
Approval by Regulatory Agencies
Biosimilars Versus Biobetters
Popular Types of Biosimilars
Recombinant Growth Factors
Monoclonal Antibodies (mAbs)
Low Molecular Weight Heparins (LMWHs)
Chapter 4 Market Breakdown by Type of Biosimilar
Chapter 5 Market Breakdown by Therapeutic Application
Chapter 6 Market Breakdown by Region
Chapter 7 Industry Structure
Chapter 8 Regulatory Aspects
Chapter 9 Patent Analysis
Chapter 10 Clinical Trials
Chapter 11 Analysis of Market Forces
Chapter 12 Company Profiles
Chapter 13 Appendix: Acronyms
For more information about this report visit https://www.researchandmarkets.com/r/x5uaab
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005585/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900